|
|
Post by peppy on Mar 17, 2020 8:54:52 GMT -5
I love you. Inhalable surfactant also in COPD, I think it would work for COPD.  |
|
|
|
Post by agedhippie on Mar 17, 2020 9:15:09 GMT -5
That's weird. This is their web site - immixbio.com/news/. As you can see it's exclusively oncology focused down to the site dedication to the co-founder's father, " Immix is dedicated to the memory of Donald E. Senn, Ph.D. who tragically lost his life to cancer at the height of a vibrant career as a biomedical scientist, and to all of the cancer patients around the world who continue their brave fight." Immix is entirely cancer focused and IMX-110, which is the drug the FDA gave that authorization to expand trial for, is for treating solid lung tumors. All their other pipeline drugs are cancer drugs and early stage. The most advanced is LMX-110 and that is recruiting for phase 1 trials so it's years off. There is nothing ARDS related. This feels like a repeat of the Epi-pen saga. There's a crisis and it's a chance to grab some publicity, but nothing comes of it. It may well be that Immix and Mannkind are doing a deal over the cancer drugs, but COVID-19 looks extremely unlikely. Every man and his dog are attempting to get the word COVID-19 and their name into the same sentence at the moment in the hopes that it boosts their share price and I cannot blame them, it would be mildly negligent not to! How is ARDS treated? Since it's a build up of water in the air sacs in the lungs it cannot really be treated with drugs. The standard approach is to manage fluids tightly, and provide oxygen. Drugs are limited to tackling secondary infections, and avoiding blood clots while you work on the fluid levels. |
|
|
|
Post by mango on Mar 17, 2020 9:18:06 GMT -5
What else could it be?
• Nrf2 activator
• Stem cell
• Corticosteroids
• Cannabinoid
|
|
|
|
Post by peppy on Mar 17, 2020 9:19:44 GMT -5
What else could it be? • Nrf2 activator • Stem cell • Corticosteroids • Cannabinoid respiratory distress in a neonatal unit. betamethsone, IV. just saying. along with Lasix, etc, etc, |
|
|
|
Post by peppy on Mar 17, 2020 9:26:15 GMT -5
standards of care to respiratory distress syndrome, there is a template. Mechanical ventilation as needed Specific treatment of RDS is intratracheal surfactant therapy. This therapy requires endotracheal intubation, which also may be necessary to achieve adequate ventilation and oxygenation. There is increasing evidence supporting use of less invasive ventilation techniques, such as nasal continuous positive airway pressure (CPAP), even in very premature infants (1). Infants with RDS who are receiving nasal CPAP and who need an increasing fraction of inspired oxygen (FIO2) have been shown to benefit from brief intubation to deliver surfactant followed by immediate extubation (1). Administration of intratracheal surfactant via a thin catheter is a newer technique that has also been shown to be beneficial in reducing the risk of BPD. Both of these techniques show a trend toward fewer cases of BPD but not fewer days of mechanical ventilation (2, 3). Surfactant hastens recovery and decreases risk of pneumothorax, interstitial emphysema, intraventricular hemorrhage, bronchopulmonary dysplasia, and neonatal mortality in the hospital and at 1 year. Options for surfactant replacement include Beractant Poractant alfa Calfactant Lucinactant Beractant is a lipid bovine lung extract supplemented with proteins B and C, colfosceril palmitate, palmitic acid, and tripalmitin; dose is 100 mg/kg every 6 hours as needed up to 4 doses. Poractant alfa is a modified porcine-derived minced lung extract containing phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins B and C; dose is 200 mg/kg followed by up to 2 doses of 100 mg/kg 12 hours apart as needed. Calfactant is a calf lung extract containing phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins B and C; dose is 105 mg/kg every 12 hours up to 3 doses as needed. Lucinactant is a synthetic surfactant with a pulmonary surfactant protein B analog, sinapultide (KL4) peptide, phospholipids, and fatty acids; dose is 175 mg/kg every 6 hours up to 4 doses. Lung compliance can improve rapidly after therapy. The ventilator peak inspiratory pressure may need to be lowered rapidly to reduce risk of a pulmonary air leak. Other ventilator parameters (eg, FIO2, rate) also may need to be reduced. www.merckmanuals.com/professional/pediatrics/respiratory-problems-in-neonates/respiratory-distress-syndrome-in-neonates |
|
|
|
Post by wyattdog on Mar 17, 2020 9:31:35 GMT -5
|
|
|
|
Post by mango on Mar 17, 2020 9:41:35 GMT -5
More potential candidates •Vasoactive Intestinal Polypeptide www.businesswire.com/news/home/20200316005965/en/RELIEF-THERAPEUTICS-HOLDING-SA-RLF-Announces-Plans• A novel CBD formulation 1012 is a novel prodrug invented by Kalytera Therapeutics, intended for the treatment of Adult Respiratory Distress Syndrome (ARDS). Designed as a bi-phosphate derivative of cannabidiol (CBD), K-1012 will be administrated intratracheally via a novel formulation expected to increase the bioavailability of CBD, known for its immunosuppressive and anti-inflammatory properties. Direct exposure to the lungs is a prerequisite in ARDS therapy, thus we have developed an aerosolized formulation. In contrast to its payload CBD, K-1012 is soluble in aqueous solution, allowing the development of an isotonic solution for an aerosolized formulation. Due to the fixed negative charge of the phosphate groups at physiological pH, K-1012 is predicted to be entrapped in the lung lumen until undergoing cleavage by various intraluminal phosphatases. Given the increased levels of lung alkaline phosphatase (ALP) in the bronchoalveolar fluid as a result of pulmonary damage, we predict ALP will liberate bioactive CBD in ARDS disease models. Progressive ARDS is closely linked to activation of inflammation. The benefits of CBD are expected to be augmented via regional targeting of K-1012 to the lung by means of the phosphate additions. In vivo efficacy studies in rodent models of E. coli LPS induced ARDS have been utilized to determine appropriate dosing and exposure time. We expect to carry out detailed ADME/PK analysis in rats as well as a non-clinical safety assessment of K-1012 in rats and dogs that will include safety pharmacology and toxicologic IND-enabling studies. To date, no effective therapy exists for ARDS, thus there remains an urgent need for a new first-line therapeutic to improve the survival of patients suffering from ARDS. The development of K-1012 will provide the first pharmacological treatment for patients with ARDS. kalytera.co/programs/preclinical/ |
|
|
|
Post by mango on Mar 17, 2020 9:43:50 GMT -5
I'm going with a dry powder surfactant, myself, but I am very excited/eager to see what it is.
|
|
|
|
Post by mango on Mar 17, 2020 9:48:02 GMT -5
|
|
|
|
Post by awesomo on Mar 17, 2020 9:50:40 GMT -5
Well it’s something, but this Innix doesn’t look like much. If you look up the major team members, Ilya Rachman, Sean Senn, and Vladimir Torchilin, not a damn thing comes up about Innix. They’re all doing other things.
I’m getting flashbacks of useless partnerships like Tanner.
|
|
|
|
Post by goyocafe on Mar 17, 2020 9:58:05 GMT -5
Well it’s something, but this Innix doesn’t look like much. If you look up the major team members, Ilya Rachman, Sean Senn, and Vladimir Torchilin, not a damn thing comes up about Innix. They’re all doing other things. I’m getting flashbacks of useless partnerships like Tanner. I would have thought a PR would include some mention of Technovax as well. Not a peep. |
|
|
|
Post by peppy on Mar 17, 2020 10:08:10 GMT -5
I'm going with a dry powder surfactant, myself, but I am very excited/eager to see what it is. if MNKD would produce surfactant, just the COPD clients would take us to the moon. surfactant worked for the meconium aspiration and RDS. The difference was HUGE> remember we would hear about the children in the hospital, no more, because they do not have to live on a ventilator for 9 months - year. They got weaned off and went home. Surfactant would send MNKD to the moon. |
|
|
|
Post by seanismorris on Mar 17, 2020 10:17:37 GMT -5
MannKind doesn’t seem to have a pipeline page on their website anymore...
|
|
|
|
Post by rfogel on Mar 17, 2020 10:21:58 GMT -5
How did Mannkind even find Immix Biopharma? I see nothing on the company's website or in their publications related to pulmonary issues or vaccines. An interview with the CEO some may find interesting: www.pmwcintl.com/ilya-michael-rachman-2019sv-qa/ |
|
|
|
Post by awesomo on Mar 17, 2020 10:27:16 GMT -5
How did Mannkind even find Immix Biopharma? I see nothing on the company's website or in their publications related to pulmonary issues or vaccines. An interview with the CEO some may find interesting: www.pmwcintl.com/ilya-michael-rachman-2019sv-qa/They’re based in LA, a couple of the founders are from UCLA Anderson. Business school connections, proximity, something like that. |
|
